These findings emphasize the importance of the interaction between Ephexin1 and Axin1, suggesting that inhibiting this interaction could be a promising strategy for the development of anticancer drugs targeting Wnt/β-catenin in active CRC. This evidence concerns the gene AXIN1 and colorectal carcinoma.